• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过数据非依赖采集质谱法发现非小细胞肺癌患者静脉血栓栓塞的蛋白质生物标志物

Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry.

作者信息

Liu Yanhong, Gao Lan, Fan Yanru, Ma Rufei, An Yunxia, Chen Guanghui, Xie Yan

机构信息

Department of Laboratory Medcine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.

Department of Respiratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, China.

出版信息

Front Oncol. 2023 Feb 9;13:1079719. doi: 10.3389/fonc.2023.1079719. eCollection 2023.

DOI:10.3389/fonc.2023.1079719
PMID:36874092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9976579/
Abstract

OBJECTIVE

Non-small cell lung cancer (NSCLC) patients present a high incidence of venous thromboembolism (VTE) with poor prognosis. It is crucial to identify and diagnose VTE early. The study aimed to identify potential protein biomarkers and mechanism of VTE in NSCLC patients proteomics research.

METHODS

Proteomic analysis of the human plasma was performed through data-independent acquisition mass spectrometry for 20 NSCLC patients with VTE, and 15 NSCLC patients without VTE. Significantly differentially expressed proteins were analyzed by multiple bioinformatics method for further biomarker analysis.

RESULTS

A total of 280 differentially expressed proteins were identified in VTE and non-VTE patients, where 42 were upregulated and 238 were downregulated. These proteins were involved in acute-phase response, cytokine production, neutrophil migration and other biological processes related to VTE and inflammation. Five proteins including SAA1, S100A8, LBP, HP and LDHB had significant change between VTE and non-VTE patients, with the area under the curve (AUC) were 0.8067, 0.8308, 0.7767, 0.8021, 0.8533, respectively.

CONCLUSIONS

SAA1, S100A8, LBP, HP and LDHB may serve as potential plasma biomarkers for diagnosis VTE in NSCLC patients.

摘要

目的

非小细胞肺癌（NSCLC）患者静脉血栓栓塞症（VTE）发生率高且预后较差。早期识别和诊断VTE至关重要。本研究旨在通过蛋白质组学研究确定NSCLC患者VTE的潜在蛋白质生物标志物及其机制。

方法

采用数据非依赖采集质谱法对20例合并VTE的NSCLC患者和15例未合并VTE的NSCLC患者的人血浆进行蛋白质组学分析。通过多种生物信息学方法分析显著差异表达的蛋白质，以进行进一步的生物标志物分析。

结果

在VTE患者和非VTE患者中总共鉴定出280种差异表达蛋白质，其中42种上调，238种下调。这些蛋白质参与急性期反应、细胞因子产生、中性粒细胞迁移以及其他与VTE和炎症相关的生物学过程。包括血清淀粉样蛋白A1（SAA1）、钙结合蛋白A8（S100A8）、脂多糖结合蛋白（LBP）、结合珠蛋白（HP）和乳酸脱氢酶B（LDHB）在内的5种蛋白质在VTE患者和非VTE患者之间有显著变化，曲线下面积（AUC）分别为0.8067、0.8308、0.7767、0.8021、0.8533。

结论

SAA1、S100A8、LBP、HP和LDHB可能作为NSCLC患者VTE诊断的潜在血浆生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/1b2e49858d86/fonc-13-1079719-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/5691bafc01c3/fonc-13-1079719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/eb252b590a9a/fonc-13-1079719-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/d3363045d1a3/fonc-13-1079719-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/522c63bfc5ab/fonc-13-1079719-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/bd6c2815ea23/fonc-13-1079719-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/7fc1f519c094/fonc-13-1079719-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/1b2e49858d86/fonc-13-1079719-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/5691bafc01c3/fonc-13-1079719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/eb252b590a9a/fonc-13-1079719-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/d3363045d1a3/fonc-13-1079719-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/522c63bfc5ab/fonc-13-1079719-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/bd6c2815ea23/fonc-13-1079719-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/7fc1f519c094/fonc-13-1079719-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edb/9976579/1b2e49858d86/fonc-13-1079719-g007.jpg

相似文献

1
Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry.通过数据非依赖采集质谱法发现非小细胞肺癌患者静脉血栓栓塞的蛋白质生物标志物
Front Oncol. 2023 Feb 9;13:1079719. doi: 10.3389/fonc.2023.1079719. eCollection 2023.
2
Discovery of plasma biomarkers with data-independent acquisition mass spectrometry and antibody microarray for diagnosis and risk stratification of pulmonary embolism.采用数据非依赖采集质谱技术和抗体微阵列发现用于肺栓塞诊断和危险分层的血浆生物标志物。
J Thromb Haemost. 2021 Jul;19(7):1738-1751. doi: 10.1111/jth.15324. Epub 2021 Apr 23.
3
Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies.血浆脂多糖结合蛋白是未来静脉血栓栓塞的生物标志物：来自发现和验证研究的结果。
J Intern Med. 2022 Sep;292(3):523-535. doi: 10.1111/joim.13502. Epub 2022 Apr 27.
4
Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.亚洲非小细胞肺癌患者静脉血栓栓塞的危险因素及预后影响
Thromb Haemost. 2014 Jun;111(6):1112-20. doi: 10.1160/TH13-11-0956. Epub 2014 Jan 30.
5
[Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].基于COMPASS-CAT风险评估模型的非小细胞肺癌患者静脉血栓栓塞症风险预测
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):340-345. doi: 10.3760/cma.j.cn112152-20191101-00707.
6
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.高血浆可溶性 P 选择素和因子 VIII 水平可预测非小细胞肺癌患者的静脉血栓栓塞：血栓-Nsclc 风险评分。
Thromb Res. 2020 Dec;196:349-354. doi: 10.1016/j.thromres.2020.09.021. Epub 2020 Sep 16.
7
Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.IA期非小细胞肺癌术后的术后静脉血栓栓塞：一项单中心前瞻性队列研究。
Thorac Cancer. 2022 May;13(9):1258-1266. doi: 10.1111/1759-7714.14373. Epub 2022 Mar 22.
8
ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌与静脉血栓栓塞的高发生率相关。
Clin Lung Cancer. 2017 Mar;18(2):156-161. doi: 10.1016/j.cllc.2016.10.007. Epub 2016 Oct 26.
9
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).ROS1 重排非小细胞肺癌与高静脉血栓栓塞率相关：来自 II 期、前瞻性、多中心、双臂试验（METROS）的分析。
Clin Lung Cancer. 2020 Jan;21(1):15-20. doi: 10.1016/j.cllc.2019.06.012. Epub 2019 Jun 18.
10
Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.制定并验证了一个列线图模型，用于评估 IA 期非小细胞肺癌患者术后静脉血栓栓塞风险。
Cancer Med. 2023 Jan;12(2):1217-1227. doi: 10.1002/cam4.4982. Epub 2022 Jun 27.

引用本文的文献

1
Low-Molecular-Weight Fucoidan Inhibits Thromboinflammation and Ameliorates Deep Vein Thrombosis via Targeting S100A8/A9.低分子量岩藻依聚糖通过靶向S100A8/A9抑制血栓炎症并改善深静脉血栓形成。
Mar Drugs. 2025 Apr 22;23(5):180. doi: 10.3390/md23050180.
2
Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis.利用蛋白质组学鉴定新型生物标志物以预测癌症相关血栓形成。
Bleeding Thromb Vasc Biol. 2024;3(Suppl 1). doi: 10.4081/btvb.2024.120. Epub 2024 May 16.

本文引用的文献

1
Proteomics in Thrombosis and Hemostasis.血栓与止血中的蛋白质组学。
Thromb Haemost. 2022 Jul;122(7):1076-1084. doi: 10.1055/a-1690-8897. Epub 2021 Nov 9.
2
Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who develop lung cancer.肺癌患者发病前中性粒细胞与淋巴细胞比值与死亡率的关系。
Cancer Causes Control. 2021 Nov;32(11):1227-1236. doi: 10.1007/s10552-021-01469-3. Epub 2021 Jul 8.
3
Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome.血小板分布宽度与原发性抗磷脂综合征的血栓事件密切相关。
Clin Rheumatol. 2021 Nov;40(11):4581-4588. doi: 10.1007/s10067-021-05843-z. Epub 2021 Jul 2.
4
Discovery of plasma biomarkers with data-independent acquisition mass spectrometry and antibody microarray for diagnosis and risk stratification of pulmonary embolism.采用数据非依赖采集质谱技术和抗体微阵列发现用于肺栓塞诊断和危险分层的血浆生物标志物。
J Thromb Haemost. 2021 Jul;19(7):1738-1751. doi: 10.1111/jth.15324. Epub 2021 Apr 23.
5
Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO).低分子量肝素（LMWH）与华法林用于血栓闭塞性脉管炎（TAO）的抗凝治疗效果
Curr Vasc Pharmacol. 2021;19(6):655-662. doi: 10.2174/1570161119666210118125424.
6
The Anticoagulant and Nonanticoagulant Properties of Heparin.肝素的抗凝和非抗凝特性。
Thromb Haemost. 2020 Oct;120(10):1371-1383. doi: 10.1055/s-0040-1715460. Epub 2020 Aug 20.
7
Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties.急性肺栓塞患者的血浆纤维蛋白凝块蛋白质组学：与凝块特性的关联。
J Proteomics. 2020 Oct 30;229:103946. doi: 10.1016/j.jprot.2020.103946. Epub 2020 Aug 16.
8
Data-Independent Acquisition Mass Spectrometry-Based Proteomics and Software Tools: A Glimpse in 2020.基于数据非依赖采集的质谱蛋白质组学及相关软件工具：2020 年的进展一瞥。
Proteomics. 2020 Sep;20(17-18):e1900276. doi: 10.1002/pmic.201900276. Epub 2020 May 19.
9
RNA expression and risk of venous thromboembolism in lung cancer.肺癌中RNA表达与静脉血栓栓塞风险
Res Pract Thromb Haemost. 2019 Dec 27;4(1):117-123. doi: 10.1002/rth2.12284. eCollection 2020 Jan.
10
Serum Lipopolysaccharide-Binding Protein Levels and the Incidence of Cardiovascular Disease in a General Japanese Population: The Hisayama Study.血清脂多糖结合蛋白水平与一般日本人群心血管疾病的发生率：日山研究。
J Am Heart Assoc. 2019 Nov 5;8(21):e013628. doi: 10.1161/JAHA.119.013628. Epub 2019 Oct 28.